MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it is exploring how palliative patients could benefit from its Ketamine home delivery platform, KetaDASH.
Ehave’s Advanced Approach to Palliative Care for Cancer Patients
Palliative care refers to specialized medical care for those patients who are suffering from a serious illness According to the World Health Organization (WHO), palliative care is an approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual. In many studies, it has been observed that the diagnosis of cancer causes a serious impact on the patients' minds, often leading many of them to develop serious mental conditions like severe depression and anxiety.
This depression, when chronic, not only interferes with the ongoing cancer treatments but could also result in suicidal thoughts in the patients. In addition to the mental pain, cancer patients also often suffer from physical pain from long-term aggressive treatments.
Ketamine as a Treatment for Depression
Ketamine was initially approved by the US Food and Drug Administration (FDA) in 1970 as an anesthetic agent to be used during surgery. Ketamine can now be purchased generically. Ehave believes that Ketamine IV drip will add an advanced approach to easing both the mental and physical pain Palliative Care patients often suffer from. Several studies have shown ketamine’s efficacy in treating physical pain and depression in palliative care patients. According to the non-profit research and educational organization, MAPS, “There has been a recent explosion of interest in ketamine, a synthetic chemical with powerful antidepressant and visionary properties.”
Renewed experiments and investigations in many clinical research settings across the globe suggest the application of psychedelics like ketamine can open new doors for treating mental illnesses like depression, anxiety, addiction, and PTSD. Though ketamine was primarily approved by FDA as a pain-relieving and anesthetic agent; now it is believed to treat and ease psychiatric conditions like depression and anxiety along with addiction.
Ehave Chief Information Officer, Alfred Farrington II, said, “Forward-thinking Technology is going to be the next wave of how we receive healthcare”; there’s no doubt KetaDASH will be the first to pave the way for advanced and improved palliative care in the world.”
Palliative Care Through Ehave’s KetaDASH
KetaDASH will be based on a dashboard that provides ketamine to patients who have had it prescribed by a physician. The dashboard will provide an objective view of performance metrics and allow KetaDASH to ensure necessary medical guidance, supervision, and support.
Ben Kaplan, CEO of Ehave said, “Our goal is to provide an IV service that will allow medical professionals to provide psychedelic-assisted therapies in the comfort and convenience of their patients' homes. We believe a large number of patients prefer a medical technician come to their home over going to a clinic.”
Additional Ehave Inc. Information
We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.
The company posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.
Please follow Ehave on Twitter @Ehaveinc1
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
Contact: Ehave Inc
Media Inquiries: Gabe Rodriguez
Phone: (623) 261-9046